Talha Badar and Team: New VTE Risk Prediction Model Validated for Asparaginase-Treated ALL
Talha Badar, Hematologist-Oncologist at Mayo Clinic Comprehensive Cancer Center, posted on X:
”Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Asparaginase-Treated ALL
Happy to contribute in this effort by ALL NCTN:
High VTE rates persist in asparaginase-treated ALL despite prophylaxis.
Externally validated VTE risk model using D-dimer and hemoglobin at diagnosis.”
Read the full article here.
Title: Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Asparaginase-Treated ALL
Authors: Daniela R. Anderson, Radhika Gangaraju, Wafik G. Sedhom, Eva N. Hamulyák, Tzu-Fei Wang, Kristen M O’Dwyer, Brian J. Carney, Chandrasekar Muthiah, Michaela Liedtke, Talha Badar, Shai Shimony, Renana Robinson, Kristen Sanfilippo, Andriy Derkach, Shira Naomi Dinner, Bart J. Biemond, David Nemirovsky, Leah A. Goldberg, Anjani D. Kapadia, Hannah Levavi, Michal Bar-Natan, Grace Van Hyfte, Karan Bansal, Marc Carrier, Jill Fulcher, Anke M. Gerrits, Mark R. Litzow, Selina M Luger, Guru Subramanian Guru Murthy, Marlise R. Luskin, Ofir Wolach, William Shomali, Jeffrey I. Zwicker, Wendy A Stock, Avi Leader
Stay updated with Hemostasis Today.
-
Nov 8, 2025, 05:31Phenotyping of Human Platelets by Daisie Yates
-
Nov 8, 2025, 04:35Inaugural Women In Hematology US Focus Meeting 2025 Officially Commenced
-
Nov 7, 2025, 06:59Stephen Cornelissen is Celebrating an Extraordinary Milestone at Australian Red Cross Lifeblood
-
Nov 7, 2025, 06:56Reza Shojaei on Leadership in the Blood and Plasma Sector
-
Nov 7, 2025, 06:52Rachel Margolis-Goodman Announces Groundbreaking Expension of Versiti Blood Research Institute
-
Nov 7, 2025, 06:46What’s New in HIT from THANZ Webinar Series
-
Nov 7, 2025, 03:30Abdallah Othman About Cardiac Vasculature
-
Nov 7, 2025, 03:29Aabha Divya: Thrilled to Share Our Latest Publication in Annals of Thoracic Surgery Short Reports!
-
Nov 7, 2025, 03:28Shantel Holcomb: Boston Scientific is Investing in Innovative Solutions to Improve Outcomes for Patients With CAD